Diabetes management: Cipla bags CDSCO regulatory nod for distribution, marketing of Afrezza (insulin human) Inhalation Powder in India

Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream. Afrezza starts working in as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals. The effect of Afrezza lasts for about 2-3 hours and it closely resembles the body’s own response to insulin. This is the noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

Umang Vohra, Managing Director and Global CEO, Cipla Limited, said, “Having pioneered inhalation therapy in India, we are proud to extend our innovation portfolio to diabetes management by partnering with MannKind for distribution of Afrezza. Cipla at its core is committed to redefining patient experiences and this advancement reflects that vision. By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively.”